慢性肾脏病成人心力衰竭住院负担与结局
本研究基于前瞻性CRIC队列3791例慢性肾脏病(CKD)患者,分析心力衰竭(HF)住院率、30天再住院率及HF住院与CKD进展和死亡的风险。结果显示HF住院粗率为5.8/100人年,低eGFR和高尿白蛋白肌酐比(ACR)者住院率更高,20.6%发生30天再住院,HF住院与CKD进展和全因死亡风险增加相关。
要点
- CKD患者HF住院粗率为5.8/100人年,射血分数保留型HF住院率高于射血分数降低型。
- eGFR<30 ml/min/1.73 m2者HF住院率比>45者高2.2倍,尿ACR≥300 mg/g者高2.6倍。
- 2年内HF住院与CKD进展和全因死亡风险增加相关,2次以上住院风险更高。
核心结论
- CKD患者HF住院和再住院率高,低eGFR和高尿ACR者更高,HF住院与CKD进展和死亡风险增加相关。
研究设计与样本
- 前瞻性CRIC队列研究,纳入3791例CKD成人,基线测量eGFR和尿ACR,随访HF住院及结局。
主要发现
- HF住院粗率为5.8/100人年,射血分数保留型HF住院率高于射血分数降低型。
- 与eGFR>45 ml/min/1.73 m2相比,eGFR 30-44和<30的调整率比分别为1.7和2.2。
- 与尿ACR<30 mg/g相比,尿ACR 30-299和≥300 mg/g的调整率比分别为1.9和2.6。
- 20.6%的参与者发生30天HF再住院。
- 2年内HF住院与CKD进展风险增加相关(1次:HR 1.93,95%CI 1.40-2.67;2次及以上:HR 2.14,95%CI 1.30-3.54)。
临床怎么用
- 对CKD患者应关注HF预防和治療,尤其低eGFR和高尿ACR者。
- CKD患者发生HF住院后需警惕CKD进展和死亡风险,加强随访管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data on rates of heart failure (HF) hospitalizations, recurrent hospitalizations, and outcomes related to HF hospitalizations in chronic kidney disease (CKD) are limited. OBJECTIVES: This study examined rates of HF hospitalizations and re-hospitalizations within a large CKD population and evaluated the burden of HF hospitalizations with the risk of subsequent CKD progression and death. METHODS: The prospective CRIC (Chronic Renal Insufficiency Cohort) study measured the estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (ACR) at baseline. The crude rates and rate ratios of HF hospitalizations and 30-day HF re-hospitalizations were calculated using Poisson regression models. Cox regression was used to assess the association of the frequency of HF hospitalizations within the first 2 years of follow-up with risk of subsequent CKD progression and death. RESULTS: Among 3,791 participants, the crude rate of HF admissions was 5.8 per 100 person-years (with higher rates of HF with preserved ejection fraction vs. HF with reduced ejection fraction). The adjusted rate of HF was higher with a lower eGFR (vs. eGFR >45 ml/min/1.73 m2); the rate ratios were 1.7 and 2.2 for eGFR 30 to 44 and <30 ml/min/1.73 m2 (vs. >45 ml/min/1.73 m2), respectively. Similarly, the adjusted rates of HF hospitalization were significantly higher in those with higher urine ACR (vs. urine ACR <30 mg/g); the rate ratios were 1.9 and 2.6 for urine ACR 30 to 299 and ≥300 mg/g, respectively. Overall, 20.6% of participants had a subsequent HF re-admission within 30 days. HF hospitalization within 2 years of study entry was associated with greater adjusted risks for CKD progression (1 hospitalization: hazard ratio [HR]: 1.93; 95% confidence interval [CI]: 1.40 to 2.67; 2+ hospitalizations: HR: 2.14; 95% CI: 1.30 to 3.54) and all-cause death (1 hospitalization: HR: 2.20; 95% CI: 1.71 to 2.84; 2+ hospitalizations: HR: 3.06; 95% CI: 2.23 to 4.18). CONCLUSIONS: Within a large U.S. CKD population, the rates of HF hospitalizations and re-hospitalization were high, with even higher rates across categories of lower eGFR and higher urine ACR. Patients with CKD hospitalized with HF had greater risks of CKD progression and death. HF prevention and treatment should be a public health priority to improve CKD outcomes.
引用
- Bansal N, Zelnick L, Bhat Z, et al. Burden and Outcomes of Heart Failure Hospitalizations in Adults With Chronic Kidney Disease. J Am Coll Cardiol. 2019. PMID: 31146814. doi:10.1016/j.jacc.2019.02.071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。